VEGFA anticorps (AA 111-161)

N° du produit ABIN6150085

L’anticorps Lapin Polyclonal anti-VEGFA a été validé pour WB, IHC, IP et IF. Il convient pour détecter VEGFA dans des échantillons de Humain. Il y a 1 publication disponible.

Aperçu rapide pour VEGFA anticorps (AA 111-161) (ABIN6150085)

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFA est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF)

Détail du produit anti-VEGFA anticorps

Épitope: AA 111-161

Séquence: PHQGQHIGEM SFLQHNKCEC RPKKDRARQE KKSVRGKGKG QKRKRKKSRY K

Réactivité croisée: Humain, Souris, Rat

Attributs du produit: Polyclonal Antibodies

Immunogène: A synthetic peptide corresponding to a sequence within amino acids 111-161 of human VEGF (NP_001165094).

Isotype: IgG

Information d'application

Indications d'application: WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200,IP,1:50 - 1:100

Commentaires:

HIGH QUALITY

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Références pour anticorps anti-VEGFA (ABIN6150085)

Qiu, Zhou, Kang, Ding, Yu, Tan, Deng: "Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model." dans: Scientific reports, Vol. 4, pp. 4324, (2015) (PubMed).

Détails sur VEGFA

Antigène: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Autre désignation: VEGFA

Sujet: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.,VEGFA,MVCD1,VEGF,VPF,L VEGFA,VEGF A,Cancer,Invasion and Metastasis,Signal Transduction,Cell Biology & Developmental Biology,Apoptosis,Growth factor,VEGF,Endocrine & Metabolism,Immunology & Inflammation,Cytokines,Cardiovascular,Angiogenesis,Angiogenic growth factors,Hypoxia,VEGFA

Poids moléculaire: 15-27 kDa/34-45 kDa

ID gène: 7422

UniProt: P15692

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling